Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $11.46 to $11.90
• 50-Day Range: $7.01 to $12.16
• 52-Week Range: $3.30 to $12.43
• Volume: 2.49 million shs
• Average Volume: 1.62 million shs
• Market Capitalization: $1.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.57
• Consensus Rating: Moderate Buy

Adaptive Biotechnologies Stock Analysis - MarketRank™

Adaptive Biotechnologies scored higher than 66% of companies evaluated by MarketBeat, and ranked 361st out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Adaptive Biotechnologies has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.92) to ($0.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adaptive Biotechnologies is -12.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adaptive Biotechnologies is -12.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Adaptive Biotechnologies has a P/B Ratio of 8.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.28% of the float of Adaptive Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

Adaptive Biotechnologies has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Adaptive Biotechnologies has recently decreased by 7.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adaptive Biotechnologies does not currently pay a dividend.

Dividend Growth

Adaptive Biotechnologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.79

Percentage of Shares Shorted

6.28% of the float of Adaptive Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

Adaptive Biotechnologies has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Adaptive Biotechnologies has recently decreased by 7.37%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.66

News Sentiment

Adaptive Biotechnologies has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Adaptive Biotechnologies this week, compared to 5 articles on an average week.

Search Interest

Only 5 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

7 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $519,977.00 in company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Adaptive Biotechnologies is held by insiders.

Percentage Held by Institutions

99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADPT Stock Analysis - Frequently Asked Questions

How have ADPT shares performed this year?

Adaptive Biotechnologies' stock was trading at $5.99 at the start of the year. Since then, ADPT shares have increased by 94.5% and is now trading at $11.65.
View the best growth stocks for 2025 here.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) issued its earnings results on Thursday, May, 1st. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.08. Adaptive Biotechnologies's quarterly revenue was up 25.2% compared to the same quarter last year.
Read the conference call transcript.

When did Adaptive Biotechnologies IPO?

Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADPT
• CIK: 1478320
• Web: www.constructionpartners.net
• Phone: (206) 659-0067
• Fax: 206-659-0667
• Employees: 790
• Year Founded: 2009

Price Target and Rating

• Average Stock Price Target: $10.57
• High Stock Price Target: $15.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: -9.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$159.49 million
• Net Margins: -74.84%
• Pretax Margin: -74.87%
• Return on Equity: -62.79%
• Return on Assets: -24.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.92
• Quick Ratio: 2.82

Sales & Book Value

• Annual Sales: $189.53 million
• Price / Sales: 9.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: 8.50

Miscellaneous

• Outstanding Shares: 151,917,000
• Free Float: 142,194,000
• Market Cap: $1.77 billion
• Optionable: Optionable
• Beta: 1.80